t
On 20 September 2022, Dechra Pharmaceuticals PLC granted share awards over Ordinary Shares to Directors Ian Page (3,580 shares), Paul Sandland (2,293 shares), and Tony Griffin (1,655 shares). These nil cost awards were made under the Dechra 2021 Deferred Bonus Plan and represent 20% of their annual bonus for the 2022 financial year. The awards will vest after a two-year deferral period.
| Date | 20 Sept 2022 |
| Time | 16:44:16 |
| Category | Director/PDMR dealings |
| ID | 0415A |
Dechra - 2022 Annual Financial Report
20 September 2022
Dechra Pharmaceuticals PLC
(the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs)
The Company announces that on 20 September 2022 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2021 Deferred Bonus Plan:
|
Name of individual |
Director |
Type of award |
Number of shares subject to award |
|
Ian Page |
Director |
DBP Award - nil cost option |
3,580 |
|
Paul Sandland |
Director |
DBP Award - nil cost option |
2,293 |
|
Tony Griffin |
Director |
DBP Award - conditional award |
1,655 |
In accordance with the Directors' Remuneration Policy, 20% of the annual bonus earned in respect of the Company's 2022 financial year has been deferred into a share award. The awards will vest at the end of a deferral period of two years.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the Market Abuse Regulation.
Notification of Dealing Form
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Ian Page |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Director |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Dechra Pharmaceuticals PLC |
||||
|
b) |
LEI code |
213800J4UVB5OWG8VX82 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each
ISIN: GB0009633180 |
||||
|
b) |
Nature of the transaction |
Grant of award over Ordinary Shares under the Company's Deferred Bonus Plan |
||||
|
c) |
Price(s) and volumes(s) |
|
||||
|
d) |
Aggregated information - Aggregate volume - Price |
N/A
|
||||
|
e) |
Date of the transaction |
2022-09-20 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Paul Sandland |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Director |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Dechra Pharmaceuticals PLC |
||||
|
b) |
LEI code |
213800J4UVB5OWG8VX82 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each
ISIN: GB0009633180 |
||||
|
b) |
Nature of the transaction |
Grant of award over Ordinary Shares under the Company's Deferred Bonus Plan |
||||
|
c) |
Price(s) and volumes(s) |
|
||||
|
d) |
Aggregated information - Aggregate volume - Price
|
N/A
|
||||
|
e) |
Date of the transaction |
2022-09-20 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Tony Griffin |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Director |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Dechra Pharmaceuticals PLC |
||||
|
b) |
LEI code |
213800J4UVB5OWG8VX82 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each
ISIN: GB0009633180 |
||||
|
b) |
Nature of the transaction |
Grant of award over Ordinary Shares under the Company's Deferred Bonus Plan |
||||
|
c) |
Price(s) and volumes(s) |
|
||||
|
d) |
Aggregated information - Aggregate volume - Price |
N/A
|
||||
|
e) |
Date of the transaction |
2022-09-20 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
For further information, please contact:
Melanie Hall, Company Secretary
Telephone: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com.
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.